Review Article
Volume 10 Issue 4 - 2020
Lung Fibrosis after Coronavirus Disease (COVID)-19: Is there Any Potential Treatment?
Fanny Fachrucha*, Adityo Wibowo, Mia Elhidsi and Galoeh Adyasiwi
Department Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Indonesia
*Corresponding Author: Fanny Fachrucha, Department Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Indonesia.
Received: February 25, 2021; Published: March 22, 2021




Abstract

Coronavirus Disease 2019 (Covid-19) become a health problem worldwide since its outbreak in December 2019. In the course of its pathogenesis, Covid-19 provides sequelae, especially in the lungs in the form of pulmonary fibrosis. The challenge currently being faced is in the management and prevention of sequelae due to Severe Acute Respiratory Syndrome Corona Virus 2 (SARS Cov2) virus infection. Lung sequelae affects high morbidity to post Covid-19 patient. Therapy and proper management are needed to prevent lung sequelae due to SARS Cov2 virus infection. Potential treatments to reduce lung fibrosis is still become a question among clinicians and need more research.

Keywords: Antifibrotic; Covid-19; Lung Fibrosis; Lung Sequelae

References

  1. Zhou S., et al. “Imaging features and evolution on CT in 100 COVID-19 pneumonia patients in Wuhan, China”. European Radiology 4 (2020): 1-9.
  2. Pan F., et al. “Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19)”. Radiology3 (2020): 715-721.
  3. Ding X., et al. “Chest CT findings of COVID-19 pneumonia by duration of symptoms”. European Journal of Radiology 127 (2020): 1-6.
  4. Lechowicz K., et al. “COVID-19: the potential treatment of pulmonary fibrosis associated with SARS-CoV-2 infection”. Journal of Clinical Medicine6 (2020): 1-20.
  5. Wigen J., et al. “Converging pathways in pulmonary fibrosis and Covid-19 – the fibrosis link to disease severity”. Respiratory Medicine (2020): 1-5.
  6. Ojo AS., et al. “Pulmonary fibrosis in Covid-19 survivors: Predictive Factors and Risk Reduction Strategies”. Pulmonary Medicine (2020): 1-10.
  7. Zuo W., et al. “SARS coronavirus and lung fibrosis”. Molecular Biology of the SARS-Coronavirus (2009): 247-258.
  8. Derynck R., et al. “Differentiation plasticity regulated by TGF-beta family proteins in development and disease”. Nature Cell Biology 9 (2007): 1000-1004.
  9. Delpino MV., et al. “SARS-CoV-2 pathogenesis: imbalance in the renin-angiotensin system favors lung fibrosis”. Frontier in Cellular and Infection Microbiology 10 (2020): 1-5.
  10. Kobayashi T., et al. “Bidirectional role of IL-6 signal in pathogenesis of lung fibrosis”. Respiratory Research1 (2015): 1-14.
  11. García LF. “Immune response, inflammation, and the clinical spectrum of COVID-19”. Frontiers in Immunology 11 (2020): 1-13.
  12. Dufour AM., et al. “Interleukin-6 and type-I collagen production by systemic sclerosis fibroblass are differentially regulated by interleukin-17a in the presence of transforming growth factor-beta 1”. Frontiers in Immunology 9 (2018): 1-13.
  13. Miao Y., et al. “Potential treatments for COVID-19 related cytokine storm - beyond corticosteroids”. Frontiers in Immunology 11 (2020): 1-3.
  14. Gubernatorova EO., et al. “IL-6: relevance for immunopathology of SARS-CoV-2”. Cytokine and Growth Factor Review 53 (2020): 13-24.
  15. McGonagle D., et al. “The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease”. Autoimmunity Review 6 (2020): 1-7.
  16. Kolahian S., et al. “Immune mechanisms in pulmonary fibrosis”. American Journal of Respiratory Cell and Molecular Biology3 (2016): 309-322.
  17. Inoshima I., et al. “Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary fibrosis in mice”. American Journal of Physiology Lung Cellular and Molecular Physiology 286 (2004): 1038-1044.
  18. Ni W., et al. “Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19”. Critical Care 24 (2020): 1-10.
  19. Seifirad S. “Pirfenidone: A novel hypothetical treatment for COVID-19”. Medical Hypotheses 144 (2020): 1-5.
  20. Knüppel L., et al. “A Novel antifibrotic mechanism of nintedanib and pirfenidone: inhibition of collagen fibril assembly”. The American Journal of Respiratory Cell and Molecular Biology1 (2017): 77-90.
  21. Wu Y., et al. “Plasminogen improves lung lesions and hypoxemia in patients with COVID-19”. QJM: An International Journal of Medicine8 (2020): 539-545.
  22. Bikdeli B., et al. “COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up”. Journal of The American College of Cardiology23 (2020): 2950-2973.
  23. Wang J., et al. “Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series”. Journal of Thrombosis and Haemostasis7 (2020): 1752-1755.
  24. Whyte CS., et al. “Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19”. Journal of Thrombosis and Haemostasis7 (2020): 1548-1555.
  25. Tang N.,et al. “Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia”. Journal of Thrombosis and Haemostasis4 (2020): 844-847.
  26. Tang N., et al. “Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy”. Journal of Thrombosis and Haemostasis5 (2020):1094-1099.
  27. Shi C., et al. “The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective clinical study”. Medxrix (2020).
  28. Miesbach W., et al. “COVID-19: coagulopathy, risk of thrombosis, and the rationale for anticoagulation”. Clinical Applied Thrombosis/Hemostasis 26 (2020): 1-7.
  29. Jeong JH., et al. “Novel TGF-β1 inhibitor antagonizes TGF-β1-induced epithelial-mesenchymal transition in human A549 lung cancer cells”. Journal of Cellular Biochemistry1 (2019): 977-987.
  30. X Xu., et al. “Effective treatment of severe COVID-19 patients with tocilizumab”. Proceedings of the National Academy of Science of the United States of America20 (2020): 10970-10975.
  31. Gubernatorova EO., et al. “IL-6: relevance for immunopathology of SARS-CoV-2”. Cytokine and Growth Factor Review 53 (2020): 13-24.
  32. Guaraldi G., et al. “Tocilizumab in patients with severe COVID-19: a retrospective cohort study”. Lancet Rheumatology8 (2020):474-484.
  33. Wang JJ., et al. “Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities”. Pharmacology and Therapeutics 215 (2020): 1-9.
Citation: Fanny Fachrucha., et al. “Lung Fibrosis after Coronavirus Disease (COVID)-19: Is there Any Potential Treatment?”. EC Pulmonology and Respiratory Medicine 10.4 (2021): 27-33.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


April Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the April issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for upcoming Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before May 04, 2021.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to editor@ecronicon.uk